Sarkoma Ewing

01Pathophysiology

Ewing sarcoma arises from a neuroectodermal progenitor cell and is driven by a characteristic balanced chromosomal translocation. In approximately 85 to 90 percent of cases, the translocation is t(11;22)(q24;q12), which fuses the EWSR1 gene on chromosome 22 to the FLI1 gene on chromosome 11. The resulting EWS-FLI1 fusion protein acts as an aberrant transcription factor that drives uncontrolled cell proliferation, blocks differentiation, and promotes survival of the tumor cells. A smaller subset (10 to 15 percent) harbors variant translocations such as t(21;22) producing EWS-ERG, but the underlying oncogenic mechanism is the same: deregulated transcriptional activity from a chimeric EWS protein.

The tumor preferentially involves the diaphysis and metadiaphysis of long bones, which distinguishes it from osteosarcoma that favors the metaphysis. The femur is the single most common site, followed by the pelvis, tibia, and fibula. Flat bones (pelvis, scapula, ribs) are involved more frequently than in osteosarcoma, and pelvic tumors tend to present later with larger tumor burden, conferring a worse prognosis.

Pain occurs because the rapidly proliferating tumor infiltrates through the medullary cavity, destroys cortical bone in a permeative pattern, and elevates the periosteum. As the periosteum is lifted and re-deposited in successive layers, the classic "onion-skin" (lamellated) periosteal reaction forms on imaging. A soft tissue mass frequently accompanies the bony lesion because the tumor breaks through the cortex and extends into surrounding soft tissues. Constitutional symptoms such as fever, elevated inflammatory markers, and leukocytosis arise because the tumor can elaborate cytokines, creating a clinical picture that closely mimics osteomyelitis, a classic exam distractor.

The tumor is classified histologically as a small round blue cell tumor, a group that also includes lymphoma, rhabdomyosarcoma, and neuroblastoma. All of these appear as sheets of monotonous, small cells with high nuclear-to-cytoplasmic ratios and scant cytoplasm. Therefore, immunohistochemistry and molecular studies are essential to differentiate Ewing sarcoma from its histologic look-alikes. Ewing sarcoma cells characteristically express CD99 (MIC2) on the cell surface, although CD99 is not entirely unique to Ewing sarcoma and must be paired with molecular confirmation of the fusion transcript.

02Classification and Clinical Manifestation

Ewing sarcoma is part of the Ewing sarcoma family of tumors (ESFT), which share the same translocation-driven biology but differ by site of origin.

Clinical manifestations can be further organized by disease extent:

03Diagnostic Workup

Workup logic. When a teenager presents with progressive bone pain, the first step is always a plain radiograph. The combination of a permeative lytic lesion in the diaphysis with an onion-skin periosteal reaction should immediately raise suspicion for Ewing sarcoma. The next step is MRI of the entire involved bone to define the full extent of the tumor within the marrow cavity and any soft tissue extension, which is essential for surgical planning.

Once the imaging is suspicious, a tissue biopsy is required before any treatment. The biopsy must be performed by, or in coordination with, the surgeon who will perform the definitive resection, because a poorly placed biopsy tract can compromise future limb-salvage surgery. Histologically, the pathologist sees uniform small round blue cells. CD99 positivity on immunohistochemistry supports the diagnosis but is not sufficient alone because CD99 can be expressed by lymphoblastic lymphoma and other small round blue cell tumors. Therefore, molecular confirmation with FISH or RT-PCR demonstrating the EWS-FLI1 fusion transcript is the gold standard for definitive diagnosis.

Simultaneously, metastatic staging is completed with CT of the chest (for lung metastases), whole-body bone scan or PET-CT (for skeletal metastases), and bilateral bone marrow biopsies (for marrow involvement). Serum LDH is obtained as a prognostic biomarker: a markedly elevated LDH at diagnosis indicates a larger disease burden and is associated with inferior outcomes.

04Management and Treatment

Treatment logic. Ewing sarcoma is a chemosensitive tumor, and multi-agent systemic chemotherapy is the backbone of therapy. Treatment begins with neoadjuvant (induction) chemotherapy using the VDC/IE protocol, which is the current standard of care. This regimen alternates cycles of vincristine, doxorubicin, and cyclophosphamide (VDC) with cycles of ifosfamide and etoposide (IE), administered every 2 weeks with growth factor support (G-CSF).

The purpose of neoadjuvant chemotherapy is twofold: it treats potential micrometastatic disease early, and it reduces the primary tumor size to facilitate local control. After approximately 12 weeks, the degree of tumor necrosis at the time of surgical resection is assessed. Greater than 90 percent necrosis correlates with improved prognosis.

Local control follows neoadjuvant chemotherapy. Surgical resection with wide margins is preferred whenever it is technically feasible and functional outcomes are acceptable. For tumors in locations where complete resection would cause unacceptable morbidity (such as the pelvis or spine), definitive radiation therapy is used instead. Radiation may also be added post-operatively if surgical margins are positive or close.

After local control, adjuvant chemotherapy using the same VDC/IE regimen is continued to eliminate residual microscopic disease. The total duration of chemotherapy spans approximately 30 to 49 weeks.

Contraindications and precautions to be aware of:

• Doxorubicin carries a risk of dose-dependent cardiotoxicity. Cumulative lifetime dose must be monitored (generally not to exceed 375 to 450 mg/m${}^2^2$ in pediatric protocols). Serial echocardiography is required during treatment.

• Ifosfamide can cause hemorrhagic cystitis, which is prevented by co-administration of mesna (a uroprotective agent). It is also nephrotoxic and may cause Fanconi syndrome.

• Cyclophosphamide also requires mesna and adequate hydration for bladder protection.

• Vincristine causes dose-limiting peripheral neuropathy; dose capping at 2 mg per dose is standard.

For patients who present with metastatic disease, the same chemotherapy backbone is used with intensification strategies. Patients with isolated pulmonary metastases who achieve complete remission may benefit from bilateral whole-lung irradiation (15 to 18 Gy) as consolidation. The role of high-dose chemotherapy with autologous stem cell rescue remains investigational and is generally reserved for very high-risk presentations.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students lose points on Ewing sarcoma questions is by confusing it with osteomyelitis. The vignette will describe a teenager with bone pain, fever, elevated ESR, and an aggressive-looking bone lesion. Students who anchor on the fever and elevated inflammatory markers reflexively choose osteomyelitis without carefully examining the imaging description. The critical discriminator is the location and imaging pattern: Ewing sarcoma involves the diaphysis with an onion-skin periosteal reaction, while osteomyelitis in children targets the metaphysis and typically lacks a large associated soft tissue mass.

The second common trap is confusing Ewing sarcoma with osteosarcoma. Both occur in teenagers and involve long bones, but the exam will almost always provide enough information to distinguish them. Osteosarcoma sits in the metaphysis, produces a sunburst pattern and Codman triangle on X-ray, and shows malignant osteoid on biopsy. Ewing sarcoma sits in the diaphysis, produces onion-skin layering, and shows small round blue cells on biopsy.

Another high-yield testing point is the histologic category. When a vignette describes a biopsy showing "sheets of small round blue cells" in a bone lesion of a teenager, the answer is almost always Ewing sarcoma. However, the examiner may test whether you know how to confirm it. CD99 positivity supports but does not confirm the diagnosis. The definitive confirmatory test is molecular detection of the EWS-FLI1 fusion via FISH or RT-PCR.

Finally, remember the racial epidemiology. Ewing sarcoma is overwhelmingly a disease of White/European-descent populations and is exceedingly rare in Black and Asian patients. If the vignette describes a primary bone tumor in a Black adolescent, the answer is far more likely to be osteosarcoma than Ewing sarcoma. This demographic detail is a reliable discriminating clue on exam questions.

The core competency being tested is the ability to integrate patient demographics (age, race), lesion location (diaphysis vs. metaphysis), imaging pattern (onion-skin vs. sunburst), histologic appearance (small round blue cells vs. malignant osteoid), and molecular confirmation into a single diagnostic framework, and to resist the distraction of systemic inflammatory signs that mimic infection.